Evicenter
MarkdownMedical informationP&T meetings
Lysergide (DT120)

Generalized anxiety disorder

Also known as MM120
Launch
Not announced
Last updated
199 sources

Clinical evidence

MMED008

105 evidence topics · 15 sources

Objective
Location and study date
Study dates in the registry
MilestoneRegistry record
Study start (actual)“2022-08-24”
Primary completion (actual)“2023-10-06”
Study completion (actual)“2023-11-27”
First posted“2022-06-07”
Results first posted“2025-03-20”
Study design
Registry design fields
FieldRegistry record
Allocation“Randomized”
Interventional model“Parallel Assignment”
Masking“Quadruple”
Phase“Phase 2”
Other study ID“MMED008”
Rationale for the dose levels and the placebo control
Eligibility criteria
Key exclusion criteria in the protocol: psychiatric history and substance use

“Prior history (lifetime diagnosis) or known first-degree relative (i.e., mother/father/full siblings) with a lifetime diagnosis of schizophrenia spectrum, or other psychotic disorder or bipolar disorder (bipolar I, bipolar II or cyclothymic disorder)” (opens the source at this quote in a new tab)

“Lifetime diagnosis of Posttraumatic Stress Disorder” (opens the source at this quote in a new tab)

“Other current psychiatric disorders that, in the opinion of the Investigator, may confound the results of the study (e.g., major depressive disorder, obsessive-compulsive disorder,” (opens the source at this quote in a new tab)

“History of alcohol or substance use disorder within 12 months prior to Screening (Visit 1) (includes diagnosis of alcohol or drug use disorder per the MINI)” (opens the source at this quote in a new tab)

“Unwillingness or inability to discontinue prohibited concomitant medications, supplements or other therapeutics (prescription or over-the-counter)” (opens the source at this quote in a new tab)

“Treatment with deep brain stimulation (DBS), vagus nerve stimulation (VNS), electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) within 3 months prior to Screening (Visit 1) or a plan to receive treatment with any of these from the time of providing informed consent until End of Study” (opens the source at this quote in a new tab)

Treatment
Dosing session procedures and monitoring
Study outcomes
Rationale for using hamilton anxiety rating scale Dose-Response at week 4 as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Completion by arm in the registry
ArmStartedCompletedNot completed
Placebo“39”“26”“13”
Lysergide 25 µg“39”“29”“10”
Lysergide 50 µg“40”“29”“11”
Lysergide 100 µg“40”“33”“7”
Lysergide 200 µg“40”“30”“10”
Baseline characteristics
Baseline demographics and disease characteristics by arm
CharacteristicPlacebo (n = 39)25 µg (n = 39)50 µg (n = 36)100 µg (n = 40)200 µg (n = 40)
Age, median (IQR), y“37 (28.5-47.5)”View highlighted excerpt for this quote“35 (30.5-43.0)”View highlighted excerpt for this quote“47 (33.0-57.3)”View highlighted excerpt for this quote“41 (29.0-55.5)”View highlighted excerpt for this quote“38.5 (33.8-55.0)”View highlighted excerpt for this quote
Female, No. (%)“26 (66.7)”View highlighted excerpt for this quote“20 (51.3)”View highlighted excerpt for this quote“20 (55.6)”View highlighted excerpt for this quote“16 (40.0)”View highlighted excerpt for this quote“28 (70.0)”View highlighted excerpt for this quote
White, No. (%)“30 (76.9)”View highlighted excerpt for this quote“33 (84.6)”View highlighted excerpt for this quote“29 (80.6)”View highlighted excerpt for this quote“36 (90.0)”View highlighted excerpt for this quote“33 (82.5)”View highlighted excerpt for this quote
Black or African American, No. (%)“6 (15.4)”View highlighted excerpt for this quote“3 (7.7)”View highlighted excerpt for this quote“2 (5.6)”View highlighted excerpt for this quote“1 (2.5)”View highlighted excerpt for this quote“3 (7.5)”View highlighted excerpt for this quote
Hispanic or Latino, No. (%)“8 (20.5)”View highlighted excerpt for this quote“5 (12.8)”View highlighted excerpt for this quote“6 (16.7)”View highlighted excerpt for this quote“6 (15.0)”View highlighted excerpt for this quote“6 (15.0)”View highlighted excerpt for this quote
Time from GAD diagnosis, median (IQR), y“11.0 (4.5-18.8)”View highlighted excerpt for this quote“7.0 (3.2-14.0)”View highlighted excerpt for this quote“12.9 (6.0-17.4)”View highlighted excerpt for this quote“11.2 (3.1-20.3)”View highlighted excerpt for this quote“11 (5.8-20.7)”View highlighted excerpt for this quote
HAM-A score, mean (SD)“30.3 (6.6)”View highlighted excerpt for this quote“30.2 (6.1)”View highlighted excerpt for this quote“30.3 (5.7)”View highlighted excerpt for this quote“29.3 (6.4)”View highlighted excerpt for this quote“31.0 (7.0)”View highlighted excerpt for this quote
CGI-S score, mean (SD)“4.9 (0.6)”View highlighted excerpt for this quote“4.9 (0.8)”View highlighted excerpt for this quote“4.9 (0.6)”View highlighted excerpt for this quote“4.8 (0.8)”View highlighted excerpt for this quote“5.1 (0.7)”View highlighted excerpt for this quote
MADRS score, mean (SD)“27.6 (9.7)”View highlighted excerpt for this quote“25.4 (7.6)”View highlighted excerpt for this quote“27.7 (8.3)”View highlighted excerpt for this quote“26.5 (8.0)”View highlighted excerpt for this quote“28.9 (8.3)”View highlighted excerpt for this quote
Continued psychotherapy during trial, No. (%)“9 (23.1)”View highlighted excerpt for this quote“3 (7.7)”View highlighted excerpt for this quote“11 (27.5)”View highlighted excerpt for this quote“5 (12.5)”View highlighted excerpt for this quote“7 (17.5)”View highlighted excerpt for this quote
Comorbid major depression, No. (%)“17 (43.6)”View highlighted excerpt for this quote“12 (30.8)”View highlighted excerpt for this quote“17 (47.2)”View highlighted excerpt for this quote“18 (45.0)”View highlighted excerpt for this quote“15 (37.5)”View highlighted excerpt for this quote
Comorbid social anxiety disorder, No. (%)“9 (23.1)”View highlighted excerpt for this quote“6 (15.4)”View highlighted excerpt for this quote“5 (13.9)”View highlighted excerpt for this quote“4 (10.0)”View highlighted excerpt for this quote“5 (12.5)”View highlighted excerpt for this quote
Comorbid panic disorder, No. (%)“7 (17.9)”View highlighted excerpt for this quote“5 (12.8)”View highlighted excerpt for this quote“4 (11.1)”View highlighted excerpt for this quote“2 (5.0)”View highlighted excerpt for this quote“5 (12.5)”View highlighted excerpt for this quote
SSRI or SNRI taper at enrollment, No. (%)“25 (64.1)”View highlighted excerpt for this quote“25 (64.1)”View highlighted excerpt for this quote“28 (77.8)”View highlighted excerpt for this quote“21 (52.5)”View highlighted excerpt for this quote“16 (40.0)”View highlighted excerpt for this quote
Benzodiazepine taper at enrollment, No. (%)“9 (23.1)”View highlighted excerpt for this quote“6 (15.4)”View highlighted excerpt for this quote“9 (25.0)”View highlighted excerpt for this quote“2 (5.0)”View highlighted excerpt for this quote“14 (35.0)”View highlighted excerpt for this quote
Efficacy results
Primary endpoint: MCP-Mod dose-response for HAM-A change at Week 4

“A significant MM120 dose-response relationship was demonstrated at both week 4 (primary outcome) and week 8 (key secondary outcome) based on changes from baseline in HAM-A score.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“At week 4, the adjusted critical value was 2.032 and the candidate dose-response models of sigmoid Emax 1 through 4, Emax, and linear observed absolute test statistics of 3.294, 3.149, 3.133, 1.448, 3.471, and 2.971, respectively. Therefore, 5 of the 6 models, including the linear, Emax, and multiple sigmoid Emax variants, met the significance threshold.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For the primary outcome, the dose-response relationship assessed using the MCP-Mod method for change in HAM-A score at week 4 was statistically significant for the 100-µg and the 200-µg dose groups vs placebo (least-squares mean difference, −5.0 points [95% CI, −9.6 to −0.4 points] with 100 µg of MM120 and −6.0 points [95% CI, −9.8 to −2.0 points] with 200 µg of MM120) but the 25-µg and 50-µg dose groups did not reach significance vs placebo (least-squares mean difference, −1.2 points [95% CI, −6.0 to 3.5 points] with 25 µg of MM120 and −1.8 points [95% CI, −7.6 to 4.0 points] with 50 µg of MM120)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Primary endpoint as posted on the registry
ArmMean change from baseline to Week 4, model averaging (95% CI)Mean difference from placebo (95% CI)
Placebo“-14.23 (-17.83 to -10.63)”Not applicable
Lysergide 25 µg“-15.35 (-17.62 to -13.09)”“-1.24 (-6.01 to 3.53)”
Lysergide 50 µg“-16.05 (-19.40 to -12.71)”“-1.82 (-7.65 to 4.00)”
Lysergide 100 µg“-19.22 (-21.73 to -16.70)”“-5.02 (-9.60 to -0.44)”
Lysergide 200 µg“-20.09 (-22.87 to -17.31)”“-5.95 (-9.84 to -2.06)”
HAM-A change from baseline by week: observed-case ANCOVA differences from placebo
Week25 µg50 µg100 µg200 µg
Week 1“−4.3 (−8.5 to −0.1)”View highlighted excerpt for this quote“−2.5 (−6.7 to 1.7)”View highlighted excerpt for this quote“−8.1 (−12.3 to −3.9)”View highlighted excerpt for this quote“−6.0 (−10.2 to −1.8)”View highlighted excerpt for this quote
Week 2“−3.4 (−7.5 to 0.8)”View highlighted excerpt for this quote“−1.5 (−5.7 to 2.8)”View highlighted excerpt for this quote“−7.1 (−11.3 to −2.9)”View highlighted excerpt for this quote“−7.5 (−11.6 to −3.3)”View highlighted excerpt for this quote
Week 4“−3.4 (−7.7 to 0.9)”View highlighted excerpt for this quote“−0.9 (−5.2 to 3.3)”View highlighted excerpt for this quote“−7.6 (−11.8 to −3.4)”View highlighted excerpt for this quote“−5.5 (−9.7 to −1.3)”View highlighted excerpt for this quote
Week 8“−2.9 (−7.6 to 1.8)”View highlighted excerpt for this quote“0.85 (−3.9 to 5.6)”View highlighted excerpt for this quote“−4.3 (−8.9 to 0.3)”View highlighted excerpt for this quote“−5.5 (−10.2 to −0.8)”View highlighted excerpt for this quote
Week 12“−4.3 (−9.3 to 0.8)”View highlighted excerpt for this quote“−3.2 (−8.2 to 1.9)”View highlighted excerpt for this quote“−7.7 (−12.6 to −2.8)”View highlighted excerpt for this quote“−7.4 (−12.4 to −2.4)”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Sheehan Disability Scale total score at Week 12
ArmObserved mean (SD) change from baselineDifference from placebo in mean change95% CI of the difference
Placebo“-8.2 (8.61)”Not applicableNot applicable
Lysergide 25 μg“-10.8 (7.72)”“-2.59”“(-7.10 to 1.91)”
Lysergide 50 μg“-9.0 (9.17)”“-0.83”“(-5.70 to 4.03)”
Lysergide 100 μg“-15.1 (5.78)”“-6.86”“(-10.89 to -2.83)”
Lysergide 200 μg“-13.1 (7.51)”“-4.93”“(-9.33 to -0.53)”
EQ-5D-5L visual analog scale at Week 12
ArmObserved mean (SD) change from baselineDifference from placebo in mean change95% CI of the difference
Placebo“11.7 (18.24)”Not applicableNot applicable
Lysergide 25 μg“17.0 (18.53)”“5.31”“(-4.65 to 15.27)”
Lysergide 50 μg“13.2 (13.97)”“1.55”“(-7.34 to 10.45)”
Lysergide 100 μg“17.7 (13.68)”“6.04”“(-2.61 to 14.70)”
Lysergide 200 μg“17.3 (19.40)”“5.64”“(-4.37 to 15.65)”
Pittsburgh Sleep Quality Index global score at Week 12
ArmObserved mean (SD) change from baselineDifference from placebo in mean change95% CI of the difference
Placebo“-4.3 (4.22)”Not applicableNot applicable
Lysergide 25 μg“-5.5 (4.01)”“-1.25”“(-3.48 to 0.99)”
Lysergide 50 μg“-4.8 (3.88)”“-0.55”“(-2.77 to 1.67)”
Lysergide 100 μg“-5.9 (4.13)”“-1.64”“(-3.84 to 0.56)”
Lysergide 200 μg“-4.9 (4.11)”“-0.60”“(-2.83 to 1.62)”
Patient Global Impression of Severity and of Change at Week 12
ArmPGI-S difference from placebo in mean changePGI-S 95% CIPGI-C observed mean (SD)PGI-C difference from placeboPGI-C 95% CI
PlaceboNot applicableNot applicable“2.2 (0.98)”Not applicableNot applicable
Lysergide 25 μg“-0.34”“(-0.91 to 0.24)”“1.8 (0.71)”“-0.36”“(-0.83 to 0.10)”
Lysergide 50 μg“-0.30”“(-0.94 to 0.34)”“1.8 (1.00)”“-0.36”“(-0.90 to 0.17)”
Lysergide 100 μg“-0.47”“(-1.05 to 0.11)”“1.5 (0.67)”“-0.71”“(-1.16 to -0.25)”
Lysergide 200 μg“-0.37”“(-1.01 to 0.26)”“1.7 (0.98)”“-0.51”“(-1.04 to 0.01)”
Sexual dysfunction (ASEX) at Week 12
ArmFemales with sexual dysfunction, n (%)Males with sexual dysfunction, n (%)
Placebo“6 (33.3)”“1 (12.5)”
Lysergide 25 μg“4 (25.0)”“3 (23.1)”
Lysergide 50 μg“10 (66.7)”“1 (7.1)”
Lysergide 100 μg“6 (46.2)”“2 (10.0)”
Lysergide 200 μg“7 (33.3)”“0 (0)”
Safety results
Adverse events in the safety population by arm
Event, No. (%)Placebo (n = 39)25 µg (n = 39)50 µg (n = 40)100 µg (n = 40)200 µg (n = 40)
At least 1 TEAE“22 (56.4)”View highlighted excerpt for this quote“30 (76.9)”View highlighted excerpt for this quote“36 (90.0)”View highlighted excerpt for this quote“39 (97.5)”View highlighted excerpt for this quote“40 (100)”View highlighted excerpt for this quote
Any treatment-related TEAE“16 (41.0)”View highlighted excerpt for this quote“29 (74.4)”View highlighted excerpt for this quote“32 (80.0)”View highlighted excerpt for this quote“38 (95.0)”View highlighted excerpt for this quote“40 (100)”View highlighted excerpt for this quote
Moderate AE“10 (25.6)”View highlighted excerpt for this quote“12 (30.8)”View highlighted excerpt for this quote“20 (50.0)”View highlighted excerpt for this quote“23 (57.5)”View highlighted excerpt for this quote“28 (70.0)”View highlighted excerpt for this quote
Visual perception changes“4 (10.3)”View highlighted excerpt for this quote“18 (46.2)”View highlighted excerpt for this quote“30 (75.0)”View highlighted excerpt for this quote“37 (92.5)”View highlighted excerpt for this quote“40 (100)”View highlighted excerpt for this quote
Nausea“3 (7.7)”View highlighted excerpt for this quote“3 (7.7)”View highlighted excerpt for this quote“11 (27.5)”View highlighted excerpt for this quote“16 (40.0)”View highlighted excerpt for this quote“24 (60.0)”View highlighted excerpt for this quote
Headache“9 (23.1)”View highlighted excerpt for this quote“5 (12.8)”View highlighted excerpt for this quote“9 (22.5)”View highlighted excerpt for this quote“14 (35.0)”View highlighted excerpt for this quote“11 (27.5)”View highlighted excerpt for this quote
Euphoric mood“1 (2.6)”View highlighted excerpt for this quote“2 (5.1)”View highlighted excerpt for this quote“5 (12.5)”View highlighted excerpt for this quote“11 (27.5)”View highlighted excerpt for this quote“6 (15.0)”View highlighted excerpt for this quote
Mydriasis“1 (2.6)”View highlighted excerpt for this quote“1 (2.6)”View highlighted excerpt for this quote“7 (17.5)”View highlighted excerpt for this quote“8 (20.0)”View highlighted excerpt for this quote“4 (10.0)”View highlighted excerpt for this quote
Hyperhidrosis“0”View highlighted excerpt for this quote“1 (2.6)”View highlighted excerpt for this quote“4 (10.0)”View highlighted excerpt for this quote“9 (22.5)”View highlighted excerpt for this quote“5 (12.5)”View highlighted excerpt for this quote
Suicidal ideation reported as an adverse event in the registry
ArmAffected / at risk (%)
Placebo“1/39 (2.56%)”
Lysergide 25 μg“1/39 (2.56%)”
Lysergide 50 μg“2/40 (5.00%)”
Lysergide 100 μg“2/40 (5.00%)”
Lysergide 200 μg“0/40 (0.00%)”
Study limitations
Summary

The trial randomized 198 participants at 22 outpatient sites in the United States to a single dose of lysergide capsules (25, 50, 100, or 200 µg) or placebo, with 12 weeks of follow-up and no study-related psychotherapy. The phase 3 trials use an orally disintegrating tablet, so the phase 2b results were obtained with a different formulation.

  • Primary analysis and reported effect size: the prespecified MCP-Mod primary analysis with multiple imputation gave a least-squares mean difference from placebo at Week 4 of −5.0 points (95% CI, −9.6 to −0.4) for 100 µg. The 7.6-point difference (Cohen d = 0.88) that company announcements report for Week 4 is the publication's secondary outcome at Week 4. The publication states that change in HAM-A score from baseline was analyzed by analysis of covariance without imputation (observed cases only), while missing primary end point data were imputed by multiple imputation; the registry results state that missing data were not imputed for non-key secondary efficacy endpoints.
  • Multiplicity: only the primary and key secondary outcomes were controlled for type I error; other hypothesis tests, including the Week 12 difference of −7.7 points and the response and remission rates, were not adjusted for multiple comparisons.
  • Functional unblinding: the authors state that the perceptible drug effects may have led to unblinding, and approximately 85% of participants correctly identified assignment to active treatment. Efficacy was rated by central raters blinded to protocol, treatment allocation, and visit.
  • Dosing session monitors: two monitors were present throughout each session, and the authors state that confounding effects of interpersonal interactions remain a possibility.
  • Missing data: 147 of 198 randomized participants (74.2%) completed the study, and the authors describe the dropout rate as slightly higher than in studies of similar molecules.
  • Population: participants were physically healthy with limited psychiatric comorbidities, discontinued anxiolytic and antidepressant medications before dosing, and 83.0% were White; 18% received psychotherapy outside the trial.
  • Sample size: 36 to 40 participants per arm in the full analysis set; analyses by sex and other characteristics were not conducted because of insufficient statistical power.
  • Adverse event figures for visual perceptual changes, nausea, and headache in the company publication announcement differ from those in the journal article (for example, nausea at 100 µg 42.5% versus 40.0%).
Limitations stated in the publication

“Despite dosing session monitors explicitly not providing a systematic psychotherapeutic intervention, confounding effects of interpersonal interactions remain a possibility.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Second, the perceptible drug effects of MM120 may have led to unblinding, which could have influenced the outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Third, the primary outcome and key secondary outcome were strictly controlled for type I error, but the other hypothesis tests were not adjusted for multiple comparisons. Fourth, the dropout rate, though similar across groups, was slightly higher than in studies of similar molecules.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This higher dropout rate may be due to the 12-week duration of the trial, the required discontinuation of GAD medications, and the absence of an extension phase with opportunities for open-label treatment. Fifth, the participants were physically healthy with limited psychiatric comorbidities, potentially enhancing the tolerability of transient AEs. Sixth, the process of tapering participants from prohibited psychoactive medications ensured MM120 was assessed as a monotherapy; however, we did not address concomitant use of other pharmacotherapies. Seventh, some participants engaged in psychotherapy outside the trial, which may have affected dosing-day experiences and efficacy outcomes, though this was the case for only 18% of participants. Eighth, the study population was inclusive in terms of sex and age but was racially and ethnically less diverse than the general population of people with GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote